The University of Oxford enrolled the first patients in human trials for the SARS-CoV-2 vaccine at the historic University of Oxford after the UK’s Health Secretary announced the great nation was “throwing everything” behind the study. This study investigates the treatments for COVID-19 along with a possible vaccine.
Held out as one of the most prominent candidates, ChAdOx1 nCoV-19 would be in development in a best-case scenario by fall 2020, reports the University of Oxford. Under normal circumstances, even at high speed the development of a commercially safe vaccine will take between 12 to 18 moths, reports ABC.
The Oxford Study
Presently, the University of Oxford study involves healthy volunteers that must fall between the ages of 18 and 55, but reports are that the demographic could expand if the study shows success. The scale up of vaccine product is ongoing as reported by TrialSite News.
UK Government Announces more Funds to Combat COVID-19
Last week, UK Health Secretary Matt Hancock announced a total of about $65 million worth of funding to fund another project—yet another vaccine clinical trial at London’s Imperial University is due to commence in June.
Many Vaccines in Development
The world’s governments, academic research centers, and research-focused providers, as well as the private sector, has come together in a furious race to develop a successful vaccine to address SARS-CoV-2. TrialSite News offered a chart of many of these candidates, including the World Health Organization updates. The reality however, as reported by TrialSite News, is that vaccines take time and a Plan B must be drawn up.